The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products
The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products
This study plans to investigate whether using electronic cigarettes (e-cigarettes) or skin
 patches containing nicotine affects switching from smoking conventional combustible (burning)
 cigarettes.
This study proposes to assess the relative role of nicotine dose and route of delivery in
 affecting successful switching from combustible cigarettes to e-cigarettes, as well as
 concomitant reductions in ad libitum cigarette smoking and exposure to harmful and
 potentially harmful constituents of combustion. The strategy will be to assess adoption of
 e-cigarette use and concomitant reduction in ad libitum smoking of subjects' usual brands of
 cigarettes over an 8-week period, during which they will receive nicotine or non-nicotine
 e-cigarettes, and nicotine skin patches. The nicotine patches will not be used as a
 therapeutic treatment in this study, but rather as a way to manipulate the nicotine dose,
 while varying the rate and route of nicotine delivery. Behavioral or "habit" aspects of
 e-cigarette use will be controlled for by the groups receiving non-nicotine e-cigarettes.
 Initially the study design included placebo patch control conditions, but due to limitations
 in budget and period of support, enrollment in these these arms was discontinued. All
 participants currently receive active nicotine patches.
Inclusion Criteria:

 -  Smoke an average of at least 10 cigarettes per day;

 -  Have smoked at least one cumulative year;

 -  Have an expired air CO reading of at least 10ppm;

 -  Have a body weight of > 110 lbs. (50 kg) and ≤ 300 lbs. (136 kg);

 -  Are able to read and understand English;

 Potential subjects of child bearing potential must agree to use acceptable contraception
 during their participation in this study. Potential subjects must agree to avoid the
 following during their participation in this study:

 -  Participation in any other nicotine-related modification strategy outside of this
 protocol;

 -  Use of tobacco products other than cigarettes, including pipe tobacco, cigars, snuff,
 and chewing tobacco;

 -  Use of e-cigarettes other than the ones provided during the study;

 -  Use of experimental (investigational) drugs or devices;

 -  Use of illegal drugs;

 -  Use of exclusionary medications.

 Exclusion Criteria:

 -  Seeking treatment for nicotine dependence.

 -  Hypertension - systolic BP > 160 mm Hg, diastolic BP > 100 mm Hg. Individuals with a
 history of hypertension may be allowed to participate in the study if the study
 physician or medical provider determines that the condition is stable and will not
 jeopardize the individual's safety.

 -  Hypotension (with symptoms) - systolic BP < 90 mm Hg, diastolic BP < 60 mm Hg.

 -  Coronary heart disease with symptoms (e.g., chest pain)

 -  Heart attack in the past year

 -  Cardiac rhythm disorder (irregular heart rhythm with symptoms)

 -  Chest pain in the last month (unless history indicates a non-cardiac source)

 -  Symptomatic heart disorder such as heart failure

 -  Advanced liver or kidney disease that requires medication or dialysis, paracentesis

 -  Major gastrointestinal illness (e.g. Celiac disease, Crohn's dx Ulcerative Colitis)

 -  Bleeding stomach ulcers in the past 30 days

 -  Lung disease that requires oxygen

 -  Major brain disorder (including stroke with residual deficit, brain tumor, and seizure
 disorder)

 -  Migraine headaches that occur more frequently than once per week

 -  Recent, unexplained fainting spells

 -  Problems giving blood samples

 -  Diabetes with insulin use or with HbA1C over 7%

 -  Current cancer or treatment for cancer in the past six months (except basal or
 squa-mous cell skin cancer)

 -  HIV, Hepatitis B, or Hepatitis C

 -  History of Tuberculosis or recent positive purified protein derivative (PPD)

 -  Other major medical condition (as determined by study physician)

 -  Currently symptomatic psychiatric disease (as determined by study physician)

 -  Psychosis, bipolar disorder, or psychiatric hospitalization within the past 12 months

 -  Suicidal ideation (thinking about ways to commit suicide) (within the past 12 months)
 or a lifetime occurrence of attempted suicide;

 -  Current depression - The Patient Health Questionnaire PHQ-9 for Depression will be
 used to screen for current (within 2 weeks) depression. Potential subjects who score
 >9 (or who score >0 on item #9 ("Thoughts that you would be better off dead, or of
 hurting yourself in some way") will be excluded from study participation, and, at the
 discretion of the study physician, referred to appropriate psychiatric treatment;

 -  Pregnant or nursing mothers

 -  Use (within the past 30 days) of:

 -  Illegal drugs (or if the urine drug screen is positive for tetrahydrocannabinol
 (THC), Cocaine, Amphetamine, Opiates, Methamphetamines, phencyclidine (PCP),
 Benzodiazepines, or Barbiturates), unless recent use of prescription Opiates or
 Benzodiazepines were taken for management of acute symptoms (e.g., tooth
 extraction, recent surgery);

 -  Experimental (investigational) drugs;

 -  Psychiatric medications including antidepressants (selective serotonin reuptake
 inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs),
 tricyclic antidepressant (TCAs), monoamine oxidase inhibitors (MAOIs), St. John's
 Wort), lithium, anti-psychotics or any other medications that are known to affect
 smoking cessation (e.g. clonidine);

 -  Phentermine, triptans, tryptophan, linezolid, dextromethorphan, opiates (unless
 taken for management of acute symptoms), tramadol, or dopamine agonists;

 -  Any agents that have documented correlation with increased incidence of
 valvulopathy and/or pulmonary hypertension (e.g., cyproheptadine, trazodone,
 nefazodone, amoxapine, tricyclic antidepressants, mirtazapine, pergolide,
 ergotamine, methysergide) (or anticipated use during the study);

 -  Wellbutrin, bupropion, Zyban, Chantix, varenicline, nicotine patch, nicotine
 replacement therapy or any other smoking cessation aid;

 -  Use of cigars, cigarillos, pipes, Hookah, dissolvable nicotine, snuff, chewing
 tobacco, or e-cigarettes

 -  Concurrent use of a serotonergic agent/combination associated with severe serotonin
 syndrome (within the past 30 days)

 -  Use of cigars, cigarillos, pipes, Hookah, dissolvable nicotine, snuff, chewing
 tobacco, or e-cigarettes within the past 30 days

 -  Self-report of consuming more than 6 alcoholic drinks on 1 or more days per week

 -  Significant adverse reaction to nicotine patch in the past

 -  Current participation or recent participation (in the past 30 days) in another smoking
 study at our Center or another research facility

 -  Current participation in another research study